The IKBIP Knockout Jurkat Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout population derived from Jurkat human T lymphoblasts, engineered for targeted disruption of the IKBIP gene. This loss-of-function model is designed for studying IKBIP-dependent signaling in a heterogeneous cell pool, avoiding clonal artifacts and enabling robust functional analyses in a leukemic T cell background.
Jurkat cells are an immortalized CD4+ T lymphocyte line established from a T cell acute lymphoblastic leukemia patient. They serve as a classic model for T cell receptor signaling, apoptosis, and NF-??B pathway investigations. Their leukemic origin and constitutive NF-??B activity provide a disease-relevant context for examining oncogenic signaling and tumor suppressor mechanisms.
IKBIP encodes a pro-apoptotic protein that negatively regulates NF-??B signaling by interacting with IKBKB (IKK??) and disrupting IKK complex activity, thereby inhibiting NF-??B transcriptional programs. IKBIP expression is induced by p53/TP53 upon DNA damage and stress stimuli, linking genotoxic stress to apoptosis. Downstream, it suppresses NF-??B targets such as BCL2 and XIAP, and promotes activation of caspases including CASP3. IKBIP also interfaces with NFKBIA (I??B??) and other IKK complex components, positioning it at a critical junction between p53-mediated stress responses and the apoptosis machinery.
In Jurkat cells, knockout of IKBIP is expected to relieve inhibition on NF-??B signaling, potentially enhancing pro-survival gene expression and conferring resistance to apoptosis. Since Jurkat cells are frequently used to study p53-induced cell death, these knockout cells offer a relevant model to dissect the crosstalk between p53 and NF-??B pathways. The polyclonal nature minimizes clonal selection biases and supports investigations into chemoresistance mechanisms and aberrant survival signaling in T cell leukemia.
These knockout cells are suited for NF-??B reporter assays, Western blotting and RT-qPCR for pathway components (e.g., RELA, NFKBIA, CASP3), and flow cytometry-based apoptosis assays using Annexin V. Applications include drug screening for NF-??B inhibitors or p53 activators, cytokine profiling, and leukemia disease modeling. The polyclonal IKBIP knockout background facilitates examination of apoptosis regulation and therapeutic vulnerabilities in T cell malignancies. For further information, please contact Ascent Research.
